Three healthcare penny stocks to explore

Published on June 22, 2021 11:02 AM PDT

Three healthcare penny stocks to explore — Image source: Chantal H,Shutterstock

Summary

CLSD stock price rose around 41% year-to-date to close at US$4.51 on June 21, 2021.
ADIL to the enter gene-testing market after approval from the US patent office. The stock was trading at US$3.18, up 10.80%, at 11:27 am ET on June 22.

MRKR stock price rose nearly 105% year-to-date to close at US$3.01 on June 21, 2021.

Penny stocks are favorites of retail investors because of their affordability. Penny stocks can be volatile and should be picked carefully. Penny stocks are companies that have a market cap of around US$60 million to US$300 million.

Here we explore three healthcare penny stocks that grabbed investors’ attention of late.

Clearside Biomedical, Inc. (NASDAQ: CLSD) is a biopharmaceutical company headquartered in Alpharetta, Georgia. It is engaged in developing treatment to prevent and restore vision in patients suffering from eye diseases.

Its market cap is US$263.7 million. Its total outstanding shares are 57,578,725. The company brought its IPO in 2016. Its revenue for the quarter ended March 31, 2021, was US$34,000, generated from licensing and other activities.

The company plans to launch its new drug XIPERE™ after receiving regulatory approval and license from the US drug authorities.

CLSD stock price rose around 41% year to date to close at US$4.51 on June 21, 2021. It was trading at US$4.536, up 0.58% at 12:11 pm ET on June 22, 2021.

Also Read: Why is 23andMe stock trending?

Source: Pixabay.

Also Read: Novan Inc. & Senseonic Inc: Two Trending Healthcare Stocks

Adial Pharmaceuticals Inc. (NASDAQ: ADIL) is a clinical-stage bio-pharmaceuticals company headquartered in Charlottesville, Virginia. It develops drugs for treating addiction and related disorders. It developed a drug codenamed AD04 for treating Alcohol Use Disorder (AUD).

The company’s total outstanding shares (excluding convertible bonds, warrants and stock options) are 18,203,523, and its market capitalization is US$57.8 million. It brought its IPO in 2018.

ADIL has not received approval for its product yet, and so, it has not generated revenue from product sales in the March quarter. As of March 31, 2021, its accumulated deficit was US$36.4 million. ADIL had purchased Purnovate, Inc. in January this year. It plans to enter the gene-testing market after receiving the Notice of Allowance from the US patent office.

ADIL stock rose around 66% year to date to close at US$2.87 on June 21, 2021.

It was trading at US$3.18, up 10.80%, at 11:27 am ET on June 22, 2021.

Also Read: 10 Hot Penny Stocks To Explore In June

Marker Therapeutics, Inc. (NASDAQ: MRKR) is a Houston, Texas-based clinical-stage immune-oncology company. It develops vaccines for various diseases.

The company is currently developing two drugs for cancer treatment.

Its total listed share outstanding is 83,013,929, and its market capitalization is US$253.6 million.

MRKR has not generated any revenue from product sales yet. It reported a net loss of US$0.16 per share diluted in the quarter ended March 31, 2021.

The stock price rose nearly 105% year to date to close at US$3.01 on June 21, 2021. It was trading at US$3.055, up 1.50%, at 11:55 am ET on June 22, 2021.

Team Kalkine Media

Author

Team Kalkine Media -
33796 Posts
Team Kalkine Media comprises of experts who understand various markets nuances and are enthusiastic and passionate to provide best possible offerings in the form of insights and stories. The team has rich experience of working across different market...

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.